From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

“I’m proud that the FTC launched a bipartisan investigation into these shadowy middlemen, and its preliminary findings prove yet again that it’s time to bust up the PBM monopoly.” Eisai ...

The lawsuit – which has been anticipated since the FTC published a damning report on the PBM sector in July – names CVS Health's Caremark, UnitedHealth Group's Optum, and Cigna's Express ...

Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...

This story was originally published by KFF Health News. While customers at Adams Family Pharmacy picked up their ...

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

The Federal Trade Commission (FTC) announced on Tuesday that it will be taking action against the online cash app and neobank Dave, which it says used "misleading marketing to deceive consumers." ...

The lawsuit, which includes additional allegations of wrongdoing, seeks a permanent injunction to prevent future violations of FTC regulations and a 2010 law that regulates online commerce.

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...

Current legislation before Congress, including the Modernizing and Ensuring PBM Accountability Act (S.2973) and the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 (S.3430), ...